Navigation Links
Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
Date:5/7/2008

NATICK, Mass., May 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced CE Mark approval and market launch of its ALTRUA(TM) family of pacemakers. ALTRUA is Boston Scientific's most advanced pacemaker and delivers enhanced therapies while maintaining its small size and battery longevity. It is the first Boston Scientific-branded pacemaker to treat bradycardia, a condition in which the heart beats too slowly -- usually less than 60 beats per minute -- depriving the body of sufficient oxygen.

"European approval of Boston Scientific's ALTRUA family of pacemakers is the latest example of the significant progress we have made rebuilding our CRM organization and reinvigorating our product pipeline," said Fred Colen, Executive Vice President, Operations and Technology, CRM. "ALTRUA's innovative technology -- enabling physicians to adjust the therapy to meet the needs of their patients -- demonstrates our renewed focus on treating bradycardia."

The ALTRUA pacemaker provides physicians with a number of diagnostic and therapeutic capabilities that enable them to tailor the therapy to specific patient requirements:

-- Multiple Atrial Ventricular (AV) Delay programming options: These

options are designed to reduce unnecessary right ventricular (RV)

pacing, without dropping ventricular beats, a key distinction from

other competitive RV pacing algorithms. The ALTRUA 50 and 60 series

also include an enhanced AV search hysteresis feature, now with an

extendable AV delay out to 400 milliseconds, providing physicians with

additional flexibility to tailor device programming for unique patient

needs.

-- Minute Ventilation (MV) Blended Sensor: This proprietary technology

treats a condition called Chronotropic Incompetence, which is the

inability of the heart to regulate its rate appropriately in response

to physical activity and emotional stress. Boston Scientific's MV

Blended sensor is the only sensor that has been shown to restore

Chronotropic Competence.

-- Ventricular Rate Regulation (VRR): This feature helps physicians manage

patients with frequent atrial arrythmias.

-- Automatic Capture: This capability is designed to offer automatic, safe

and accurate ventricular pulse management. The device checks every

heart beat to see if the lower chambers of the heart contract in

response to the delivered pulse. If no contraction is detected, a

backup pace with more energy is delivered.

The ALTRUA family of pacemakers is currently awaiting approval by the U.S. Food and Drug Administration and is not available for sale in the United States.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, regulatory approval of our products, new product launches, competitive offerings, our growth strategy, and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT: Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
2. Fraunhofer and Boston University Hosted Prestigious SME Tour
3. Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection
4. Boston Scientific Announces Results for First Quarter Ended March 31, 2008
5. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
6. Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System
7. Boston Scientific and CryoCor Announce Signing of Definitive Merger Agreement
8. Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology
9. Boston Scientific Announces Japanese Approval of Heart Failure Lead
10. Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts
11. Boston Scientific to Webcast Conference Call Discussing First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... became double board-certified in surgery and surgery of the hand by the National ... no stranger to going above and beyond in his pursuit of providing the ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company Ltd. ... the company’s orphan drug designation request covering BHV-4157 for the treatment of Spinocerebellar ... FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that is ...
(Date:5/23/2016)... ... ... blood donations in South Texas and across the nation is growing. , But according to ... are on the decline. In fact, donations across the country are at their lowest point ... the last four years alone. , There is no substitute for blood. , “We want ...
(Date:5/23/2016)... North Carolina (PRWEB) , ... May 23, 2016 ... ... automation and building management solutions and services based in Aurora, Ohio, has broken ... of established business in the Research Triangle Park area, this new location solidifies ...
Breaking Biology Technology:
(Date:3/22/2016)... OTTAWA, Ontario , PROVO ... 2016 Newborn Screening Ontario (NSO), which operates ... for molecular testing, and Tute Genomics and ... process management technology respectively, today announced the launch of ... new next-generation sequencing (NGS) testing panel. ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... March 14, 2016 NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ... week of March 21 st .  The commercials will air ... popular Squawk on the Street show. --> NXTD ... growing mobile commerce market, announces the airing of a new ...
Breaking Biology News(10 mins):